Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing an epitope-driven tuberculosis (TB) vaccine.

Anne S De Groot1, Julie McMurry, Luisa Marcon

  • 1EpiVax, Inc., Providence, RI 02903, USA. AnneD@Epivax.com

Vaccine
|March 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants.

Research square·2026
Same author

Serum Short-Chain Fatty Acids in Colorectal Cancer: Diagnostic Performance and Decoupling from Gut Producer Abundance.

Cells·2026
Same author

Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.

Human vaccines & immunotherapeutics·2026
Same author

PD-1 blockade drug holiday improves exhausted progenitor CD8 T cell (Tpex) reinvigoration by avoiding Tpex adaptive resistance.

bioRxiv : the preprint server for biology·2026
Same author

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.

The AAPS journal·2026
Same author

Intestinal epithelial cell-specific deletion of Jak2 disrupts gut homeostasis.

Scientific reports·2026

This study developed a novel tuberculosis (TB) vaccine prototype using epitope mapping. The vaccine demonstrated epitope-specific T cell responses in mice, suggesting a promising new avenue for infectious disease vaccines.

Area of Science:

  • Vaccinology
  • Immunoinformatics
  • Molecular Biology

Background:

  • Epitope-driven vaccines utilize specific protein sub-sequences (epitopes) for pathogen targeting.
  • Identifying effective epitopes involves scanning pathogen protein sequences for binding motifs to human MHC molecules.

Purpose of the Study:

  • To develop a prototype DNA vaccine for tuberculosis (TB) using bioinformatics-driven epitope selection.
  • To validate selected epitopes through T cell responses in human PBMCs and mouse models.

Main Methods:

  • EpiMer and EpiMatrix mapping of Mycobacterium tuberculosis (Mtb) proteins and ORFs to identify epitopes.
  • Validation of Mtb epitopes using T cell responses from human peripheral blood mononuclear cells (PBMCs).
  • Immunization of HLA-DR B*0101 transgenic mice with a DNA plasmid vaccine encoding 24 validated Mtb epitopes, with co-administration of rIL-15.

Related Experiment Videos

Main Results:

  • Twenty-four Mtb epitopes with at least three distinct class II MHC binding motif matches were selected.
  • Epitope-specific T cell responses were observed in mice against eight of the 24 vaccine construct epitopes.
  • The study demonstrated the feasibility of epitope-driven vaccine development through integrated bioinformatics and in vitro validation.

Conclusions:

  • A prototype epitope-driven TB vaccine was successfully developed and tested.
  • Bioinformatics tools combined with in vitro validation are effective for identifying and confirming vaccine epitopes.
  • This approach holds potential for developing novel vaccines against infectious diseases like TB.